Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (REVRI)
Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL)
Sponsor: Central Hospital, Nancy, France
Listed as NCT01956695, this PHASE2 trial focuses on Lymphoma and Relapse and remains completed. Sponsored by Central Hospital, Nancy, France, it has been updated 8 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — May 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Hospital, Nancy, France
- Centre Henri Becquerel
- Centre Hospitalier Universitaire, Amiens
- Centre Leon Berard
- Groupe Hospitalier Pitie-Salpetriere
- Institut Bergonié
- Institut Curie
- University Hospital, Clermont-Ferrand
- University Hospital, Grenoble
- University Hospital, Lille
- University Hospital, Tours
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Bordeaux, France , Clermont-Ferrand, France , Grenoble, France , Lille, France , Lyon, France , Marseille, France , Nancy, France , Paris, France , Rouen, France and 2 more locations